Drugs that contain Cilastatin Sodium; Imipenem; Relebactam

1. Drug name - RECARBRIO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8487093 MSD MERCK CO β-lactamase inhibitors
Nov, 2029

(7 years from now)

CN102827067A MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN102827067B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407A MSD MERCK CO Beta-1Actamase Inhibitors
Jan, 2029

(6 years from now)

CN101918407B MSD MERCK CO Beta-Lactam Enzyme Inhibitor
Jan, 2029

(6 years from now)

IN201003977P4 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

IN293446B MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667A2 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774A1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2231667B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

EP2666774B1 MSD MERCK CO Beta-Lactamase Inhibitors
Jan, 2029

(6 years from now)

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
EQ 500MG BASE/VIAL;500MG/VIAL;250MG/VIAL POWDER;INTRAVENOUS Prescription

availability in other generic markets.

Click on the highlighted region to filter.